Verona reports Phase IIa data for RPL554 in CF

Verona Pharma plc (LSE:VRP; NASDAQ:VRNA) reported top-line data from a Phase IIa trial in 10 cystic fibrosis patients showing that single doses of 1.5 and 6 mg RPL554 (VMX554, VRP554) both significantly increased mean forced expiratory volume in 1 second (FEV1) at four, six and eight hours vs. placebo (p<0.05 for all). RPL554 was well tolerated.

The primary endpoint of the double-blind, three-way crossover, U.K. trial is pharmacokinetics. Secondary endpoints include FEV1 over 24 hours, forced vital capacity (FVC) and safety...